Novo Nordisk A/S is set to present new phase 3 data at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress in Washington, D.C. The company will showcase results from the FRONTIER5 trial, highlighting the well-tolerated switch to investigational Mim8 prophylaxis from emicizumab in people with haemophilia A.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.